Dual endothelin-1 receptor antagonism prevents chronic intermittent hypoxia-induced cardiovascular alterations in rats Source: Annual Congress 2008 - Innovative treatments in sleep disordered breathing Year: 2008
TrkB expression is altered in hypoxia-induced pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 606s Year: 2007
Endothelin-1 receptor antagonists prevent the development of pulmonary emphysema in rats Source: Eur Respir J 2010; 35: 904-912 Year: 2010
Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension? Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018 Year: 2018
NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019
Effect of eNOS gene overexpression on the vascular reactivity of isolated pulmonary arteries of chronic hypoxic rats Source: Annual Congress 2006 - Taormina 4th ERS Lung Science Conference "hypoxia in lung biology and disease" Year: 2006
Effects of AT1 receptor blockade on pulmonary and systemic manifestations in a COPD/emphysema mouse model Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011
Overexpression of serotonin receptor 1B (5HT-1B) responsible for overflow induced experimental pulmonary arterial hypertension development Source: Annual Congress 2003 - Pathophysiology of the pulmonary circulation Year: 2003
Shroom expression is attenuated in hypoxia-induced pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 147s Year: 2006
Effects of the NO donor molsidomine on prostacyclin synthase gene expression in rats with chronic hypoxic pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 414s Year: 2001
Severe pulmonary hypertension in chronic lung disease. Long term effects on gas exchange of endothelin receptor antagonists or PDE5 inhibitors Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011
Functional upregulation of PRMT2 in chronic hypoxia-induced pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 721s Year: 2004
Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011
NMDA receptor activation promotes vascular remodeling and pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018
Effects of selective and unselective endothelin-receptor antagonists on prostacyclin synthase gene expression in pulmonary hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007
Macitentan modulates pulmonary mRNA levels of gremlin 1 in a rat model of pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019
Echocardiographyc and histomorphometric assessment of the effects of pharmacological antagonism of endothelin receptors in the Sugen 5416/hypoxia rat model of pulmonary hypertension Source: International Congress 2018 – Experimental research in pulmonary hypertension Year: 2018
Effects of combination treatments with the PPAR β/δ agonist GW0742 and the phosphodiesterase type V inhibitor, sildenafil on markers of pulmonary hypertension in hypoxic rats Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010
Oestradiol ameliorates monocrotaline pulmonary hypertension via NO, prostacyclin and endothelin-1 pathways Source: Eur Respir J 2013; 41: 1116-1125 Year: 2013